Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) ended Wednesday session in red amid volatile trading. The shares closed down -0.17 points or -10.24% at $1.49 with 2.35 million shares getting traded. Post opening the session at $1.62, the shares hit an intraday low of $1.46 and an intraday high of $1.65 and the price vacillated in this range throughout the day. The company has a market cap of $178.60 million and the numbers of outstanding shares have been calculated to be 121.31 million shares.
Idera Pharmaceuticals Inc (IDRA) announced new preclinical data demonstrating enhanced systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an inhibitor of the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO1). IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera. IDO is one of several immune checkpoints involved in tumor immune escape. IDO-1 inhibitors are currently in clinical development. These data are being presented at the AACR Annual Meeting 2016 in New Orleans, LA.
“There is an extensive body of evidence which demonstrates that modulating the tumor microenvironment is critical to a successful outcome in cancer immunotherapy”, stated Sudhir Agrawal, D.Phil., President of Research at Idera Pharmaceuticals. “In preclinical models, previously we have seen compelling systemic anti-tumor effects with intra-tumoral IMO-2125 monotherapy, in combination with inhibitors of CTLA-4, PD-1, and now, IDO.”
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) ended Wednesday session in red amid volatile trading. The shares closed down -0.80 points or -4.44% at $17.22 with 8.80 million shares getting traded. Post opening the session at $17.73, the shares hit an intraday low of $16.62 and an intraday high of $18.36 and the price vacillated in this range throughout the day. The company has a market cap of $792.51 million and the numbers of outstanding shares have been calculated to be 45.77 million shares.
Sarepta Therapeutics Inc (SRPT) a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The companys lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charleys Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; and a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Shares of Opko Health Inc. (NYSE:OPK) ended Wednesday session in red amid volatile trading. The shares closed down -0.54 points or -5.22% at $9.80 with 5.30 million shares getting traded. Post opening the session at $10.23, the shares hit an intraday low of $9.68 and an intraday high of $10.29 and the price vacillated in this range throughout the day. The company has a market cap of $5.29 billion and the numbers of outstanding shares have been calculated to be 545.84 million shares.
Opko Health Inc. (OPK) announced that it will release operating and financial results for the three months ended March 31, 2016, after the close of the U.S. financial markets on Monday, May 9, 2016.
OPKO’s senior management will provide a business update and discuss its results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time on Monday, May 9, 2016.
The conference call dial-in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, May 9, 2016, 4:30 p.m. ET
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 2590322
For those unable to participate in the conference call or webcast, a replay will be available beginning May 9, 2016 at 7:30 p.m. ET until May 15, 2016 at 11:59 p.m. ET. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 2590322.
The replay can also be accessed for a period of time on OPKO’s website at www.opko.com.